Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many people have been prescribed (a) Ozempic and (b) other weight loss medication in the last 12 months.

Ozempic is only licenced for the treatment of type 2 diabetes and can only be prescribed off-label for use in weight management. The NHS Business Services Authority (NHSBSA) collects data on the number of prescriptions dispensed in England. Between March 2024 and February 2025, 83,286 unique identified patients were dispensed Ozempic in England. The data does not specify the purpose for which it was prescribed.

The NHSBSA also holds data on the number of prescription items dispensed of weight-loss medication. Between March 2024 and February 2025, 344,927 unique identified patients in England were dispensed medicines licensed for weight loss management.

The following have been included as they are licenced for weight management: Biolide; Nevolat; Saxenda; Wegovy; Orlistat (chemical substance) (Xenical, Alli, Orlos); and Tirzepatide (chemical substance) (Mounjaro). These have also been listed in the National Health Service’s obesity treatment information page, which is available at the following link:

https://www.nhs.uk/conditions/obesity/treatment/

There may be other medicines that may be prescribed for weight loss treatment that are not included in this data. As above, the NHSBSA does not collect data on the clinical condition for which medicines have been prescribed, so this data does not specify whether patients were prescribed medicines for weight-loss or another condition.